[Media Reports] Exclusive/Inventec Smart Medical News, Executives Revealed Supply Chains in "These 2 Countries"

Good Future, a subsidiary of Inventec (2356), in order to respond to the increasing demand for circulating tumor cells testing, it has joined hands with its group partner Inventec Appliances to create a circulating tumor cells automatic testing system. Chiline CATCH", and Good Future Dr. Lin recently revealed that this system has been deployed in overseas markets and is gradually communicating with medical units in Thailand, Malaysia and other regions. It has a good chance of entering the medical supply chain of these two countries and comprehensively strengthening the group's medical layout in the Southeast Asian market.

Dr. Lin pointed out that in order to meet the huge domestic demand for tumor cell detection, the team is still racking its brains to continue to upgrade this automatic detection system. The latest CATCH HT and CATCH II models can detect up to 96 specimens per day and can simultaneously detect six biomarkers (biomakers). This greatly increases the detection energy and is expected to meet the market demand for such accurate and convenient rapid cancer detection.

Dr. Lin pointed out that the current detection range of this system includes the "ten major cancers". The most important thing is to test the blood of the subject. During the screening process, the red blood cells and white blood cells of the subject will be removed to avoid interfering with the test results. Through this system, it can be confirmed It can truly clarify the number of "tumor cells" contained in the test subject's blood, which is mainly divided into "healthy: 0-4 cells, medium risk: 5-29, high risk: more than 30 cells." Although the test cost is higher, the accuracy is better, so it has been cooperated by many institutions.

Dr. Lin said frankly that in addition to relying on the professional medical technology of the team, this system also requires the help of engineers from Inventec Appliances to jointly operate the system (CTC circulating tumor cells), so as to understand whether the tested people have tumors in their bodies. He said with a smile, "Ten years ago we said that computers would pick peanuts, but now computers can pick cells, and now they will help compile them into reports." Through three steps: early screening, target effectiveness evaluation, and postoperative follow-up, tumors and cancer cells can be effectively reduced, or the number of cells can be reduced.

Dr. Lin said that according to information released by the World Health Organization, only 5% of the world's truly healthy population is. In the face of the rapidly growing global demand for testing, Inventec Group has also entered the market through the circulating tumor cells (CTCs) automated testing equipment jointly developed by its two major subsidiaries. With the All-in-One design, it implements a fully automated testing mode of Sample-in and Data-out. It can obtain the CTC value in the blood and analyze the risk of cancer through blood testing, which has become a great pride of the biotechnology industry.

Dr. Lin revealed that many institutions, including Taipei General Hospital, have purchased Good Future's system equipment, which can be used for people's specimens to be screened in the hospital, while other people and hospitals still have to send their specimens to Good Future's testing center for testing. However, as the number of cooperative testing units in the country continues to increase, it will be more convenient for people to use this system in the future. At present, this system is also being deployed in overseas markets. The recent targets are Thailand and Malaysia, two major markets. It is expected that there will be good news this year.

Good Future Dr. Lin talks to the public about the importance of health examinations

Media reports----

United News Network

Economic Daily

Health Policy Council